Each week, a professional investor tells MoneyWeek where he'd put his money now. This week: Mike Prentis, portfolio manager, BlackRock Smaller Companies investment trust.
Our investment approach is most simply described as trying to find and invest in companies which have the potential to become much larger over the medium term. We ensure our portfolios are mainly composed of our highest-quality core holdings most have fared well in widely differing economic conditions. We have stringent criteria for our core holdings.
They must all have: proven, trustworthy management; strong market positions giving them pricing power; a clear record of earnings growth; good conversion of earnings into cash; and a sound balance sheet.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Examples of our larger core holdings include Oxford Instruments, Aveva, Ashtead, Howden Joinery, Senior and Booker. We supplement these with smaller holdings which have the potential to become core; our positions in each individual company are much smaller than in a core' company, until our confidence levels have increased.
We recognise the differing economic growth rates of emerging markets, North America, and western Europe, and seek to gain exposure to companies which are selling into strong geographical end markets.
Three companies with market caps below £100m which we believe have considerable medium term attractions are Corin, Gooch & Housego and Brainjuicer.
Corin (LSE: CRG) designs and makes a range of orthopaedic implants, with the emphasis on hips and knees. Sales of metal-on-metal hips have fallen dramatically in recent years, but Corin introduced a new range of non-metal-on-metal hips, which now represents about 60% of sales. Legacy metal-on-metal hips are now down to 5% of total sales. Total hip sales grew 41% in 2011 and are expected to continue to grow well.
Corin has also developed a new knee product which looks to have considerable competitive advantages and is due to be launched next year. Given the success of the hip product, hopes are high for the new knee. In 2011, Corin achieved sales of £47.9m and operating profits of £2.5m. In a few years, we would hope to see total sales growing at 10% plus per year, and operating margins moving to and above 10%. Currently Corin has a market cap of £23m and debt of £5m.
Gooch & Housego (LSE: GHH) is a world-leading designer and manufacturer of precision optical components and subsystems. Its historic success has been built around the Q-switch, a product used in lasers which enables a powerful light pulse to evolve. Sales are closely linked to the semiconductor sales and so are very cyclical.
In recent years, the company has sought to diversify its product range and to move more into systems and other related areas, in particular aerospace and defence, and life sciences. Whilst there had been some delays of certain major contracts, these have now all come through, and the pipeline of other prospects is encouraging.
Brainjuicer (LSE: BJU) is at the forefront of thinking in psychology and behavioural science and its application to market research. It has developed a range of juicy tools' which aim to understand how individual consumers think, rather than how they say they think. It is run by a very strong, inspirational, management team. Customers include Coca-Cola and Proctor & Gamble. Revenues and earnings have grown strongly over the last five years, and we expect this to continue.
-
Pension warning: one in five don’t know how much is going into their pensionHow to check your pension contributions and why it matters
-
50,000 power of attorney applications rejected – how to avoid common mistakesA freedom of information request shows that thousands of lasting power of attorney (LPA) applications are rejected due to errors. We explain how to avoid mistakes and reveal tips to make the process as straightforward as possible
-
Somero: trading this overlooked bargainFeatures Mechanical-screed maker Somero dominates its niche and is attractively valued. Matthew Partridge picks the best way to trade it.
-
How to find big profits in small companiesCover Story The small- and micro-cap sectors are risky and volatile. But with careful research and patience, investors could make huge gains. Matthew Partridge explains how to find the market’s top tiddlers.
-
The hidden gems on Aim, London's junior marketFeatures Aim, London’s junior market, is risky – but you can find solid stocks at low prices. Scott Longley reports.
-
Is Aim finally coming of age?Features The Aim market of mostly smaller companies has traditionally been seen as a bit of a backwater. Is it time to change that view? Matthew Partridge talks to Paul Latham and Richard Power of fund management company Octopus.
-
Fetch! The Chinese small-cap stocks to buy in the Year of the DogOpinion Each week, a professional investor tells us where she’d put her money. This week: Tiffany Hsiao of Matthews Asia selects three Chinese small-cap stocks with exciting potential.
-
Small and mid-cap stocks with big potential
Opinion Professional investor Guy Anderson of the Mercantile Investment Trust selects three small and medium-sized firms with promising prospects that the market has missed.
-
Get cheap, reliable growth from smaller companiesFeatures One of the most reliable long-term investment trends is the long-term outperformance of smaller companies over blue chips. Max King picks some of the best ways to buy into this growth.
-
Big gains from small caps
Features In an environment of middling inflation and low interest rates, small-cap stocks tend to beat big blue-chips. John Stepek explains why, and how to invest in them.
